Madrigal Pharmaceuticals ( (MDGL) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Madrigal Pharmaceuticals’ stock is climbing as analysts grow more optimistic about the company’s future, citing extended patent protection for its key drug REZDIFFRA and strong prospects for market expansion. These factors have prompted a notable round of price target increases from Wall Street, even though the company recently reported a quarterly net loss. Analysts still largely rate the stock a strong buy, betting that long-term growth will outweigh current losses. One cautionary sign for investors, however, is negative insider sentiment, with several company insiders selling shares in recent months.
More about Madrigal Pharmaceuticals
YTD Price Performance: 73.50%
Average Trading Volume: 332,982
Technical Sentiment Signal: Buy
Current Market Cap: $12.4B
For further insights into MDGL stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.